American Society of Hirudotherapy

Nitric oxide in the ECMO circuit as a treatment option for heparin-induced thrombocytopenia: A case report

Case report published in Perfusion (2026)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentClinical TrialsJoelsons D et al. · Perfusion, 2026

Abstract

IntroductionExtracorporeal membrane oxygenation (ECMO) involves the use of a synthetic circuit, which initiates a complex interplay of inflammatory and pro-coagulant responses. This intricate, self-reinforcing process results in a prothrombotic state, predisposing patients to arterial, venous, or oxygenator thrombosis. Unfractionated heparin is the standard anticoagulant chosen in ECMO patients to prevent such complications.Case ReportIn this case report our patient presented heparin-induced thrombocytopenia (HIT), a possible complication.DiscussionAlternative strategies such as bivalirudin and argatroban are possible options but due the unavailability of those medications at our institution, nitric oxide (NO) via sweep-gas flow was deemed a reasonable alternative considering it's anti-aggregant effect.ConclusionThis case report details the use of NO as a possible alternative anticoagulant strategy in a patient with ECMO complicated by HIT.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Reports use of sweep-gas nitric oxide as an unconventional anti-aggregant alternative on the ECMO circuit when bivalirudin and argatroban were unavailable to manage HIT during ECMO.

Why This Matters for Hirudotherapy

This case report describes the use of nitric oxide (NO) via sweep-gas flow as an alternative anticoagulant strategy in an ECMO patient who developed heparin-induced thrombocytopenia (HIT), when bivalirudin and argatroban were unavailable at the institution. The abstract notes NO's anti-aggregant effect as the rationale for its use and details no other management options employed. The article has no relevance to ASH's domain: the abstract does not mention hirudin, lepirudin, leeches, or any leech-derived therapy, and the focus is entirely on NO as a novel ECMO anticoagulation workaround. CAVEAT: This is a single case report with no leech-related content and no direct connection to hirudotherapy or the leech secretome.

Citation

Nitric oxide in the ECMO circuit as a treatment option for heparin-induced thrombocytopenia: A case report.

Joelsons D et al. · Perfusion, 2026

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.